Evoke Pharma (EVOK) 10-K2022 FY Annual report

Filed: 21 Mar 23, 4:16pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adherence, citizenship, constantly, constraint, contrast, decree, destroyed, ease, effectuated, element, ER, FD, feasible, filer, flow, GoodRx, illustrated, insight, intensifying, invasion, IRA, Jersey, lifted, Motegrity, navigate, NOL, obsolescence, opposed, outpace, preexisting, quantity, resurgence, retroactively, Senate, Thrifty, timeline, top, unfriendly, verifying, vitaCare, White

Removed: amending, back, bank, clinically, complaint, denied, drafting, evaluated, explanatory, fewer, fill, freely, merger, prepaid, preparing, publicly, ranged, Renshaw, Rent, responding, restriction, Rodman, settle, Silicon, successor, supplemented, thereto, tradable, transmit, unsecured, Valley, Vice, viewed, warrant

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated EVOK transcripts

EVOK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Evoke Pharma, Inc.

Solana Beach, California

We hereby consent to the incorporation by reference in Registration Statements on Form S-3 (No. 333-251614) and Form S-8 (Nos. 333-224897, 333-219960, 333-211302 and 333-191518) of Evoke Pharma, Inc. (the “Company”) of our report dated March 21, 2023, relating to the financial statements, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

/s/ BDO USA, LLP

San Diego, California

March 21, 2023

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.